A Phase IIIB, Multicentre, Multinational, Randomized, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f Day 1 to Day 5 Followed by Pergoveris Starting Day 6 to Pergoveris Starting Day 1 in Women Between 36 and 40 Years of Age Undergoing Assisted Reproductive Technique (ART) [Studio di fase IIIB multicentrico, multinazionale, randomizzato, in aperto, per confrontare l'efficacia e la sicurezza della stimolazione ovarica con GONAL f dal giorno 1 al giorno 5, seguita da Pergoveris a partire dal giorno 6, rispetto al solo Pergoverisa partire dal giorno 1, in donne di eta compresa tra 36 e 40 anni sottoposte a tecnica di riproduzione assistita (ART=assisted reproductive technique)].

Trial Profile

A Phase IIIB, Multicentre, Multinational, Randomized, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f Day 1 to Day 5 Followed by Pergoveris Starting Day 6 to Pergoveris Starting Day 1 in Women Between 36 and 40 Years of Age Undergoing Assisted Reproductive Technique (ART) [Studio di fase IIIB multicentrico, multinazionale, randomizzato, in aperto, per confrontare l'efficacia e la sicurezza della stimolazione ovarica con GONAL f dal giorno 1 al giorno 5, seguita da Pergoveris a partire dal giorno 6, rispetto al solo Pergoverisa partire dal giorno 1, in donne di eta compresa tra 36 e 40 anni sottoposte a tecnica di riproduzione assistita (ART=assisted reproductive technique)].

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Follitropin alfa (Primary) ; Follitropin alfa/lutropin alfa (Primary)
  • Indications Female infertility
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Jan 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top